New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities.
Identifieur interne : 001449 ( PubMed/Curation ); précédent : 001448; suivant : 001450New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities.
Auteurs : Sheila M. Pimentel-Elardo [Allemagne] ; Verena Buback ; Tobias A M. Gulder ; Tim S. Bugni ; Jason Reppart ; Gerhard Bringmann ; Chris M. Ireland ; Tanja Schirmeister ; Ute HentschelSource :
- Marine drugs [ 1660-3397 ] ; 2011.
Descripteurs français
- KwdFr :
- Animaux, Antiprotozoaires (isolement et purification), Antiprotozoaires (pharmacologie), Axinella (microbiologie), Cathepsine B (antagonistes et inhibiteurs), Cathepsine L (antagonistes et inhibiteurs), Composés hétérocycliques avec 4 noyaux ou plus (isolement et purification), Composés hétérocycliques avec 4 noyaux ou plus (pharmacologie), Cysteine endopeptidases (), Inhibiteurs de protéases (isolement et purification), Inhibiteurs de protéases (pharmacologie), Leishmania major (), Protéines virales (antagonistes et inhibiteurs), Spectroscopie par résonance magnétique, Streptomyces (), Trypanocides (isolement et purification), Trypanocides (pharmacologie), Trypanosoma brucei brucei (), Virus du SRAS ().
- MESH :
- antagonistes et inhibiteurs : Cathepsine B, Cathepsine L, Protéines virales.
- isolement et purification : Antiprotozoaires, Composés hétérocycliques avec 4 noyaux ou plus, Inhibiteurs de protéases, Trypanocides.
- microbiologie : Axinella.
- pharmacologie : Antiprotozoaires, Composés hétérocycliques avec 4 noyaux ou plus, Inhibiteurs de protéases, Trypanocides.
- Animaux, Cysteine endopeptidases, Leishmania major, Spectroscopie par résonance magnétique, Streptomyces, Trypanosoma brucei brucei, Virus du SRAS.
English descriptors
- KwdEn :
- Animals, Antiprotozoal Agents (isolation & purification), Antiprotozoal Agents (pharmacology), Axinella (microbiology), Cathepsin B (antagonists & inhibitors), Cathepsin L (antagonists & inhibitors), Cysteine Endopeptidases (drug effects), Heterocyclic Compounds, 4 or More Rings (isolation & purification), Heterocyclic Compounds, 4 or More Rings (pharmacology), Leishmania major (drug effects), Magnetic Resonance Spectroscopy, Protease Inhibitors (isolation & purification), Protease Inhibitors (pharmacology), SARS Virus (drug effects), Streptomyces (chemistry), Trypanocidal Agents (isolation & purification), Trypanocidal Agents (pharmacology), Trypanosoma brucei brucei (drug effects), Viral Proteins (antagonists & inhibitors).
- MESH :
- chemical , antagonists & inhibitors : Cathepsin B, Cathepsin L, Viral Proteins.
- chemical , drug effects : Cysteine Endopeptidases.
- chemical , isolation & purification : Antiprotozoal Agents, Heterocyclic Compounds, 4 or More Rings, Protease Inhibitors, Trypanocidal Agents.
- chemical , pharmacology : Antiprotozoal Agents, Heterocyclic Compounds, 4 or More Rings, Protease Inhibitors, Trypanocidal Agents.
- chemistry : Streptomyces.
- drug effects : Leishmania major, SARS Virus, Trypanosoma brucei brucei.
- microbiology : Axinella.
- Animals, Magnetic Resonance Spectroscopy.
Abstract
Four new tetromycin derivatives, tetromycins 1-4 and a previously known one, tetromycin B (5) were isolated from Streptomyces axinellae Pol001(T) cultivated from the Mediterranean sponge Axinella polypoides. Structures were assigned using extensive 1D and 2D NMR spectroscopy as well as HRESIMS analysis. The compounds were tested for antiparasitic activities against Leishmania major and Trypanosoma brucei, and for protease inhibition against several cysteine proteases such as falcipain, rhodesain, cathepsin L, cathepsin B, and viral proteases SARS-CoV M(pro), and PL(pro). The compounds showed antiparasitic activities against T. brucei and time-dependent inhibition of cathepsin L-like proteases with K(i) values in the low micromolar range.
DOI: 10.3390/md9101682
PubMed: 22072992
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001449
Links to Exploration step
pubmed:22072992Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities.</title><author><name sortKey="Pimentel Elardo, Sheila M" sort="Pimentel Elardo, Sheila M" uniqKey="Pimentel Elardo S" first="Sheila M" last="Pimentel-Elardo">Sheila M. Pimentel-Elardo</name><affiliation wicri:level="1"><nlm:affiliation>Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, Würzburg 97082, Germany. elardos@mcmaster.ca</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, Würzburg 97082</wicri:regionArea></affiliation></author><author><name sortKey="Buback, Verena" sort="Buback, Verena" uniqKey="Buback V" first="Verena" last="Buback">Verena Buback</name></author><author><name sortKey="Gulder, Tobias A M" sort="Gulder, Tobias A M" uniqKey="Gulder T" first="Tobias A M" last="Gulder">Tobias A M. Gulder</name></author><author><name sortKey="Bugni, Tim S" sort="Bugni, Tim S" uniqKey="Bugni T" first="Tim S" last="Bugni">Tim S. Bugni</name></author><author><name sortKey="Reppart, Jason" sort="Reppart, Jason" uniqKey="Reppart J" first="Jason" last="Reppart">Jason Reppart</name></author><author><name sortKey="Bringmann, Gerhard" sort="Bringmann, Gerhard" uniqKey="Bringmann G" first="Gerhard" last="Bringmann">Gerhard Bringmann</name></author><author><name sortKey="Ireland, Chris M" sort="Ireland, Chris M" uniqKey="Ireland C" first="Chris M" last="Ireland">Chris M. Ireland</name></author><author><name sortKey="Schirmeister, Tanja" sort="Schirmeister, Tanja" uniqKey="Schirmeister T" first="Tanja" last="Schirmeister">Tanja Schirmeister</name></author><author><name sortKey="Hentschel, Ute" sort="Hentschel, Ute" uniqKey="Hentschel U" first="Ute" last="Hentschel">Ute Hentschel</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011</date><idno type="RBID">pubmed:22072992</idno><idno type="pmid">22072992</idno><idno type="doi">10.3390/md9101682</idno><idno type="wicri:Area/PubMed/Corpus">001449</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001449</idno><idno type="wicri:Area/PubMed/Curation">001449</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001449</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities.</title><author><name sortKey="Pimentel Elardo, Sheila M" sort="Pimentel Elardo, Sheila M" uniqKey="Pimentel Elardo S" first="Sheila M" last="Pimentel-Elardo">Sheila M. Pimentel-Elardo</name><affiliation wicri:level="1"><nlm:affiliation>Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, Würzburg 97082, Germany. elardos@mcmaster.ca</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, Würzburg 97082</wicri:regionArea></affiliation></author><author><name sortKey="Buback, Verena" sort="Buback, Verena" uniqKey="Buback V" first="Verena" last="Buback">Verena Buback</name></author><author><name sortKey="Gulder, Tobias A M" sort="Gulder, Tobias A M" uniqKey="Gulder T" first="Tobias A M" last="Gulder">Tobias A M. Gulder</name></author><author><name sortKey="Bugni, Tim S" sort="Bugni, Tim S" uniqKey="Bugni T" first="Tim S" last="Bugni">Tim S. Bugni</name></author><author><name sortKey="Reppart, Jason" sort="Reppart, Jason" uniqKey="Reppart J" first="Jason" last="Reppart">Jason Reppart</name></author><author><name sortKey="Bringmann, Gerhard" sort="Bringmann, Gerhard" uniqKey="Bringmann G" first="Gerhard" last="Bringmann">Gerhard Bringmann</name></author><author><name sortKey="Ireland, Chris M" sort="Ireland, Chris M" uniqKey="Ireland C" first="Chris M" last="Ireland">Chris M. Ireland</name></author><author><name sortKey="Schirmeister, Tanja" sort="Schirmeister, Tanja" uniqKey="Schirmeister T" first="Tanja" last="Schirmeister">Tanja Schirmeister</name></author><author><name sortKey="Hentschel, Ute" sort="Hentschel, Ute" uniqKey="Hentschel U" first="Ute" last="Hentschel">Ute Hentschel</name></author></analytic><series><title level="j">Marine drugs</title><idno type="eISSN">1660-3397</idno><imprint><date when="2011" type="published">2011</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Antiprotozoal Agents (isolation & purification)</term><term>Antiprotozoal Agents (pharmacology)</term><term>Axinella (microbiology)</term><term>Cathepsin B (antagonists & inhibitors)</term><term>Cathepsin L (antagonists & inhibitors)</term><term>Cysteine Endopeptidases (drug effects)</term><term>Heterocyclic Compounds, 4 or More Rings (isolation & purification)</term><term>Heterocyclic Compounds, 4 or More Rings (pharmacology)</term><term>Leishmania major (drug effects)</term><term>Magnetic Resonance Spectroscopy</term><term>Protease Inhibitors (isolation & purification)</term><term>Protease Inhibitors (pharmacology)</term><term>SARS Virus (drug effects)</term><term>Streptomyces (chemistry)</term><term>Trypanocidal Agents (isolation & purification)</term><term>Trypanocidal Agents (pharmacology)</term><term>Trypanosoma brucei brucei (drug effects)</term><term>Viral Proteins (antagonists & inhibitors)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term><term>Antiprotozoaires (isolement et purification)</term><term>Antiprotozoaires (pharmacologie)</term><term>Axinella (microbiologie)</term><term>Cathepsine B (antagonistes et inhibiteurs)</term><term>Cathepsine L (antagonistes et inhibiteurs)</term><term>Composés hétérocycliques avec 4 noyaux ou plus (isolement et purification)</term><term>Composés hétérocycliques avec 4 noyaux ou plus (pharmacologie)</term><term>Cysteine endopeptidases ()</term><term>Inhibiteurs de protéases (isolement et purification)</term><term>Inhibiteurs de protéases (pharmacologie)</term><term>Leishmania major ()</term><term>Protéines virales (antagonistes et inhibiteurs)</term><term>Spectroscopie par résonance magnétique</term><term>Streptomyces ()</term><term>Trypanocides (isolement et purification)</term><term>Trypanocides (pharmacologie)</term><term>Trypanosoma brucei brucei ()</term><term>Virus du SRAS ()</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cathepsin B</term><term>Cathepsin L</term><term>Viral Proteins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en"><term>Cysteine Endopeptidases</term></keywords><keywords scheme="MESH" type="chemical" qualifier="isolation & purification" xml:lang="en"><term>Antiprotozoal Agents</term><term>Heterocyclic Compounds, 4 or More Rings</term><term>Protease Inhibitors</term><term>Trypanocidal Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiprotozoal Agents</term><term>Heterocyclic Compounds, 4 or More Rings</term><term>Protease Inhibitors</term><term>Trypanocidal Agents</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Cathepsine B</term><term>Cathepsine L</term><term>Protéines virales</term></keywords><keywords scheme="MESH" qualifier="chemistry" xml:lang="en"><term>Streptomyces</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Leishmania major</term><term>SARS Virus</term><term>Trypanosoma brucei brucei</term></keywords><keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr"><term>Antiprotozoaires</term><term>Composés hétérocycliques avec 4 noyaux ou plus</term><term>Inhibiteurs de protéases</term><term>Trypanocides</term></keywords><keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr"><term>Axinella</term></keywords><keywords scheme="MESH" qualifier="microbiology" xml:lang="en"><term>Axinella</term></keywords><keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiprotozoaires</term><term>Composés hétérocycliques avec 4 noyaux ou plus</term><term>Inhibiteurs de protéases</term><term>Trypanocides</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Magnetic Resonance Spectroscopy</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Animaux</term><term>Cysteine endopeptidases</term><term>Leishmania major</term><term>Spectroscopie par résonance magnétique</term><term>Streptomyces</term><term>Trypanosoma brucei brucei</term><term>Virus du SRAS</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Four new tetromycin derivatives, tetromycins 1-4 and a previously known one, tetromycin B (5) were isolated from Streptomyces axinellae Pol001(T) cultivated from the Mediterranean sponge Axinella polypoides. Structures were assigned using extensive 1D and 2D NMR spectroscopy as well as HRESIMS analysis. The compounds were tested for antiparasitic activities against Leishmania major and Trypanosoma brucei, and for protease inhibition against several cysteine proteases such as falcipain, rhodesain, cathepsin L, cathepsin B, and viral proteases SARS-CoV M(pro), and PL(pro). The compounds showed antiparasitic activities against T. brucei and time-dependent inhibition of cathepsin L-like proteases with K(i) values in the low micromolar range.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">22072992</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>03</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1660-3397</ISSN><JournalIssue CitedMedium="Internet"><Volume>9</Volume><Issue>10</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Marine drugs</Title><ISOAbbreviation>Mar Drugs</ISOAbbreviation></Journal><ArticleTitle>New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities.</ArticleTitle><Pagination><MedlinePgn>1682-97</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.3390/md9101682</ELocationID><Abstract><AbstractText>Four new tetromycin derivatives, tetromycins 1-4 and a previously known one, tetromycin B (5) were isolated from Streptomyces axinellae Pol001(T) cultivated from the Mediterranean sponge Axinella polypoides. Structures were assigned using extensive 1D and 2D NMR spectroscopy as well as HRESIMS analysis. The compounds were tested for antiparasitic activities against Leishmania major and Trypanosoma brucei, and for protease inhibition against several cysteine proteases such as falcipain, rhodesain, cathepsin L, cathepsin B, and viral proteases SARS-CoV M(pro), and PL(pro). The compounds showed antiparasitic activities against T. brucei and time-dependent inhibition of cathepsin L-like proteases with K(i) values in the low micromolar range.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pimentel-Elardo</LastName><ForeName>Sheila M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Julius-von-Sachs Institute for Biological Sciences, University of Würzburg, Julius-von-Sachs-Platz 3, Würzburg 97082, Germany. elardos@mcmaster.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buback</LastName><ForeName>Verena</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Gulder</LastName><ForeName>Tobias A M</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Bugni</LastName><ForeName>Tim S</ForeName><Initials>TS</Initials></Author><Author ValidYN="Y"><LastName>Reppart</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Bringmann</LastName><ForeName>Gerhard</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Ireland</LastName><ForeName>Chris M</ForeName><Initials>CM</Initials></Author><Author ValidYN="Y"><LastName>Schirmeister</LastName><ForeName>Tanja</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Hentschel</LastName><ForeName>Ute</ForeName><Initials>U</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 CA036622</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>09</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Mar Drugs</MedlineTA><NlmUniqueID>101213729</NlmUniqueID><ISSNLinking>1660-3397</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000981">Antiprotozoal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006576">Heterocyclic Compounds, 4 or More Rings</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014344">Trypanocidal Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014764">Viral Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C099456">3C-like proteinase, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="D003546">Cysteine Endopeptidases</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C416224">falcipain 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.-</RegistryNumber><NameOfSubstance UI="C446033">rhodesain</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.1</RegistryNumber><NameOfSubstance UI="D002401">Cathepsin B</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.22.15</RegistryNumber><NameOfSubstance UI="D056668">Cathepsin L</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000981" MajorTopicYN="N">Antiprotozoal Agents</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D047089" MajorTopicYN="N">Axinella</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002401" MajorTopicYN="N">Cathepsin B</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056668" MajorTopicYN="N">Cathepsin L</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003546" MajorTopicYN="N">Cysteine Endopeptidases</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006576" MajorTopicYN="N">Heterocyclic Compounds, 4 or More Rings</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018320" MajorTopicYN="N">Leishmania major</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D045473" MajorTopicYN="N">SARS Virus</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013302" MajorTopicYN="N">Streptomyces</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014344" MajorTopicYN="N">Trypanocidal Agents</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014346" MajorTopicYN="N">Trypanosoma brucei brucei</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014764" MajorTopicYN="N">Viral Proteins</DescriptorName><QualifierName UI="Q000037" MajorTopicYN="N">antagonists & inhibitors</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Streptomyces axinellae</Keyword><Keyword MajorTopicYN="N">anti-trypanosomal</Keyword><Keyword MajorTopicYN="N">marine sponge</Keyword><Keyword MajorTopicYN="N">protease inhibition</Keyword><Keyword MajorTopicYN="N">tetromycin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2011</Year><Month>09</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>09</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22072992</ArticleId><ArticleId IdType="doi">10.3390/md9101682</ArticleId><ArticleId IdType="pii">marinedrugs-09-01682</ArticleId><ArticleId IdType="pmc">PMC3210601</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Science. 2003 Jun 13;300(5626):1763-7</Citation><ArticleIdList><ArticleId IdType="pubmed">12746549</ArticleId></ArticleIdList></Reference><Reference><Citation>ChemMedChem. 2011 Feb 7;6(2):273-8</Citation><ArticleIdList><ArticleId IdType="pubmed">21275051</ArticleId></ArticleIdList></Reference><Reference><Citation>Biochem Pharmacol. 1973 Dec 1;22(23):3099-108</Citation><ArticleIdList><ArticleId IdType="pubmed">4202581</ArticleId></ArticleIdList></Reference><Reference><Citation>Acta Trop. 1993 Dec;55(4):257-61</Citation><ArticleIdList><ArticleId IdType="pubmed">8147282</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioorg Med Chem Lett. 2006 May 15;16(10):2753-7</Citation><ArticleIdList><ArticleId IdType="pubmed">16516467</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Opin Microbiol. 2006 Jun;9(3):245-51</Citation><ArticleIdList><ArticleId IdType="pubmed">16675289</ArticleId></ArticleIdList></Reference><Reference><Citation>Antimicrob Agents Chemother. 2006 Jul;50(7):2439-47</Citation><ArticleIdList><ArticleId IdType="pubmed">16801424</ArticleId></ArticleIdList></Reference><Reference><Citation>ChemMedChem. 2006 Oct;1(10):1126-41</Citation><ArticleIdList><ArticleId IdType="pubmed">16933358</ArticleId></ArticleIdList></Reference><Reference><Citation>Pharmacol Ther. 2007 Feb;113(2):354-68</Citation><ArticleIdList><ArticleId IdType="pubmed">17098288</ArticleId></ArticleIdList></Reference><Reference><Citation>Trends Microbiol. 2007 Nov;15(11):491-9</Citation><ArticleIdList><ArticleId IdType="pubmed">17997312</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Pharm Biotechnol. 2009 Jan;10(1):86-105</Citation><ArticleIdList><ArticleId IdType="pubmed">19149592</ArticleId></ArticleIdList></Reference><Reference><Citation>Int J Syst Evol Microbiol. 2009 Jun;59(Pt 6):1433-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19502329</ArticleId></ArticleIdList></Reference><Reference><Citation>J Med Chem. 2010 Mar 11;53(5):1951-63</Citation><ArticleIdList><ArticleId IdType="pubmed">20131843</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Top Med Chem. 2010;10(3):368-82</Citation><ArticleIdList><ArticleId IdType="pubmed">20166949</ArticleId></ArticleIdList></Reference><Reference><Citation>Mar Drugs. 2010;8(4):1417-68</Citation><ArticleIdList><ArticleId IdType="pubmed">20479984</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2003 Dec 18;349(25):2431-41</Citation><ArticleIdList><ArticleId IdType="pubmed">14681510</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001449 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001449 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:22072992
|texte= New tetromycin derivatives with anti-trypanosomal and protease inhibitory activities.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:22072992" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a SrasV1
| This area was generated with Dilib version V0.6.33. |  |